Document is current

Article History

Received: 25 November 2024

Accepted: 30 November 2024

First Online: 20 December 2024

Declarations

:

: All autopsies were carried out according to local legislation with the appropriate consent. Ethical approval for the use of the cases was granted by the ethical committee of Ulm University (Germany) and UZ/KU-Leuven ethical committee (Belgium). In this study, the use of seeds from human brain tissue was approved by the UZ/KU-Leuven ethical committee (S-64492) (Belgium). The use of animals was approved by the KU-Leuven ethical committee for animal the experiments conducted here (P169/2020).

: Not applicable.

: DRT received consultant speaker honorary from Biogen (USA) and Muna Therapeutics (Belgium), and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). DRT acts as vice-chair of the ISTAART professional interest area “The eye as a biomarker for AD”.CAFvA received honoraria from serving on the scientific advisory board of Biogen, Roche, Novo Nordisk, Biontech, Lilly and Dr. Willmar Schwabe GmbH &Co. KG, MindAhead UG and has received funding for travel and speaker honoraria from Biogen, Roche diagnostics AG, Novartis, Medical Tribune Verlagsgesellschaft mbH, Landesvereinigung für Gesundheit und Akademie für Sozialmedizin Niedersachsen e. V., FomF GmbH and Dr. Willmar Schwabe GmbH &Co. KG and has received research support from Roche diagnostics AG and research funding from the Innovationsfond (Fund of the Federal Joint Committee, Gemeinsamer Bundesausschuss, G-BA Grants No. VF1_2016-201; 01NVF21010; 01VSF21019). SOT acts as consultant for Muna Therapeutics (Belgium).